Literature DB >> 14563844

Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase.

Isabelle Bougie1, Martin Bisaillon.   

Abstract

Ribavirin is a broad spectrum antiviral nucleoside that displays activity against a variety of RNA and DNA viruses. Ribavirin is currently used in combination with interferon-alpha for the treatment of hepatitis C virus (HCV) infection and was recently shown to be directly incorporated by the HCV RNA polymerase into RNA products. This capacity ultimately leads to increased mutation rates and drastically reduces the viral fitness. As a first step toward elucidating the nature of the specific interaction between ribavirin and the HCV polymerase, we have utilized fluorescence spectroscopy to monitor precisely the binding of ribavirin triphosphate (RTP) to the viral polymerase. This spectroscopic approach allowed us to clearly separate the RTP binding activity from the concomitant catalytic steps. We report here the first detailed study of the binding kinetics and thermodynamic parameters involved in the interaction between RTP and an RNA polymerase. We demonstrate that RTP binds to the same active site as nucleotides. Furthermore, we provide evidence that the HCV polymerase cannot only bind to RTP but also to nonphosphorylated ribavirin, albeit with less affinity. By using various combinations of template-primers, we also demonstrate that base pairing is not involved in the initial binding of RTP to the HCV polymerase. Based on the results of circular dichroism and denaturation studies, we show that the RNA polymerase undergoes subtle conformational changes upon the binding of RTP, although the interaction does not significantly modify the stability of the protein. Finally, although metal ions are required for catalytic activity, they are not required for the initial binding of RTP to the polymerase. Such quantitative analyses are of primary importance for the rational design of new ribavirin analogues of potential therapeutic value and provide crucial insights on the interaction between RTP and the HCV RNA polymerase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563844     DOI: 10.1074/jbc.M308917200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

2.  Characterization of the DNA- and dNTP-binding activities of the human cytomegalovirus DNA polymerase catalytic subunit UL54.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Martin Bisaillon
Journal:  Biochem J       Date:  2007-11-01       Impact factor: 3.857

3.  The hantavirus nucleocapsid protein recognizes specific features of the viral RNA panhandle and is altered in conformation upon RNA binding.

Authors:  M A Mir; A T Panganiban
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 4.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Ribosomal protein S19-binding domain provides insights into hantavirus nucleocapsid protein-mediated translation initiation mechanism.

Authors:  Safder S Ganaie; Absarul Haque; Erdong Cheng; Tania S Bonny; Nilshad N Salim; Mohammad A Mir
Journal:  Biochem J       Date:  2014-11-15       Impact factor: 3.857

Review 6.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

7.  Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.

Authors:  Kristie D Ibarra; Mamta K Jain; Julie K Pfeiffer
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

8.  Affinity labeling of hepatitis C virus replicase with a nucleotide analogue: identification of binding site.

Authors:  Dinesh Manvar; Kamlendra Singh; Virendra N Pandey
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

9.  Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.

Authors:  Curtis Cooper; Susanna Naggie; Michael Saag; Jenny C Yang; Luisa M Stamm; Hadas Dvory-Sobol; LingLing Han; Phillip S Pang; John G McHutchison; Douglas Dieterich; Mark Sulkowski
Journal:  Clin Infect Dis       Date:  2016-05-25       Impact factor: 9.079

10.  Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance.

Authors:  Kristie D Ibarra; Julie K Pfeiffer
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.